The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 19, 2014

Filed:

Aug. 25, 2011
Applicants:

Hyung Sub Gwak, Daejeon, KR;

Yong Zu Kim, Daejeon, KR;

Uk IL Kim, Daejeon, KR;

Byeong Deog Park, Daejeon, KR;

Tae Kyo Park, Daejeon, KR;

Sung Ho Woo, Daejeon, KR;

Joung Yul Yun, Daejeon, KR;

Dae Yon Lee, Daejeon, KR;

Hyang Sook Lee, Daejeon, KR;

Jeong Eun Jeon, Daejeon, KR;

SE Kyoo Jeong, Daejeon, KR;

Hyung Mook Choi, Daejeon, KR;

Inventors:

Hyung Sub Gwak, Daejeon, KR;

Yong Zu Kim, Daejeon, KR;

Uk Il Kim, Daejeon, KR;

Byeong Deog Park, Daejeon, KR;

Tae Kyo Park, Daejeon, KR;

Sung Ho Woo, Daejeon, KR;

Joung Yul Yun, Daejeon, KR;

Dae Yon Lee, Daejeon, KR;

Hyang Sook Lee, Daejeon, KR;

Jeong Eun Jeon, Daejeon, KR;

Se Kyoo Jeong, Daejeon, KR;

Hyung Mook Choi, Daejeon, KR;

Assignee:

Neopharm Co., Ltd., Daejeon, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/497 (2006.01); C07D 211/32 (2006.01); A61Q 19/00 (2006.01); A61K 8/49 (2006.01); C07D 471/04 (2006.01); C07D 235/08 (2006.01);
U.S. Cl.
CPC ...
C07D 235/08 (2013.01); A61Q 19/00 (2013.01); A61K 8/4946 (2013.01); C07D 471/04 (2013.01);
Abstract

Provided are heterocyclic compounds, having effects of treating and preventing inflammatory diseases and treating skin wounds, and particularly, exhibiting effects of recovering disrupted skin barriers, mitigating inflammation, and pruritus. Also, a composition containing the compound as an effective component can be used to mitigate various inflammatory diseases and protease activated receptor-2 (PAR-2)-overexpressed diseases, and can be particularly used as a composition having an anti-inflammatory function in inflammatory skin diseases including atopic dermatitis and the like, by inhibiting PAR-2 activity.


Find Patent Forward Citations

Loading…